Connect with us

Hi, what are you looking for?


Gilead stock price ‘does not’ reflect its oncology business: Analyst

Gilead Sciences Inc (NASDAQ: GILD) ended in the green on Tuesday after a JPMorgan analyst turned bullish on the biopharmaceutical company.

Gilead stock should be worth $80 a share

Chriss Schott now rates this healthcare name at “overweight” and sees upside to $80 a share – about a 25% increase from here.

One of the more obvious reasons why he likes Gilead Sciences is its HIV franchise. The analyst wrote:

We have its HIV franchise growing a low single digit CAGR though early 2030s. During this time, we see Biktarvy remaining the dominant product with revenues growing from $10.2 billion in 2022 to $12.5 billion in 2025.

Schott sees big future for Descovy as well.

In August, the biotech company reported market-beating results for its fiscal second quarter. Gilead stock is down about 10% for the year.

Gilead Sciences has a tempting dividend yield

The Nasdaq-listed firm also has an emerging “oncology” business, which, as per the JPMorgan analyst, is entirely not reflected in the current stock price.

Gilead’s HIV business alone supports its entire market cap. With an oncology franchise we forecast to reach ~$5.0 billion in sales by 2030 as well as potential upside to lenacapravir estimates, we see shares as clearly undervalued.

Healthcare stocks are known to do well in a recession that’s likely coming. “That” with a rather lucrative 4.47% dividend yield makes it all the more attractive to buy Gilead stock here.

Shares are currently trading well below the average of their price-to-earnings multiple over the past five years.  

The post Gilead stock price ‘does not’ reflect its oncology business: Analyst appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.